Abstract:Abstract Prostate cancer is the second leading cause of male cancer death in the United States. While localized disease can be cured by radiation or surgery, metastatic prostate cancer presents a clinical challenge. Metastatic prostate cancer can initially be controlled by endocrine therapies that target the androgen receptor (AR), however, these tumors will inevitably develop resistance. This stage of the disease, termed castration-resistant prostate cancer (CRPC), is responsible for the majority of prostate cancer-specific deaths. Current treatment options for CRPC patients are not curable and highlight the need to develop novel therapeutic options that will more effectively treat the disease. Spliced mRNA molecules undergo cleavage and polyadenylation ~25 base pair downstream from a canonical 5’AAUAAA poly(A) site located within the 3’ untranslated region (UTR). Shortening of mRNA 3’UTRs through alternative polyadenylation has been found in numerous cancers leading to downregulation of tumor suppressor genes and upregulation of oncogenes. To investigate the function of alternative polyadenylation in CRPC, we conducted a loss-of-function screen of mRNA polyadenylation factors in hormone-sensitive LNCaP cells and hormone-insensitive LNCaP95 and 22Rv1 cells. We found that knockdown of the cleavage and polyadenylation specificity factor (CPSF) component, CPSF1, inhibited growth of all cell lines. To define pathways that are regulated by CPSF1 in prostate cancer, we identified CPSF1-dependent gene expression using RNA-seq and CPSF1-dependent poly(A) sites using poly(A)-ClickSeq (PAC-Seq). Gene set enrichment analysis of RNA-seq data revealed the Glycolysis Hallmark and Hypoxia Hallmark gene sets were positively regulated by CPSF1. Analysis of PAC-seq data revealed global induction of poly(A) sites distal to 3’ UTRs upon CPSF1 knockdown. By integrating these RNA-seq and PAC-seq datasets, we have identified AR-independent pathways that may be attractive for therapeutic targeting in prostate cancer. This study has revealed post-transcriptional gene regulation by CPSF1 as an important pathway used in CRPC. Citation Format: Kiel T. Tietz, Braedan M. McClukey, Sarah A. Munro, Conor R. Miller, Scott M. Dehm. Alternative polyadenylation as a therapeutic vulnerability in prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr A022.

Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth

Comprehensively Analysis of Splicing Factors to Construct Prognosis Prediction Classifier in Prostate Cancer.

Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer

Systematic Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Prostate Cancer

Abstract 2197: Dysregulated Alternative Splicing Landscape Identifies Intron Retention As a Hallmark and Spliceosome As a Therapeutic Vulnerability in Aggressive Prostate Cancer

SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer

Prognostic Value of Survival-Associated Splicing Factor SNRPA1 Overexpression and Its Potential Mechanism in Liver Cancer

The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis.

Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1

Study of prognostic splicing factors in cancer using machine learning approaches

Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing

Defining splicing factor requirements for androgen receptor variant synthesis in advanced prostate cancer

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

Identification of Bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma

Abstract A022: Alternative polyadenylation as a therapeutic vulnerability in prostate cancer

SR Splicing Factors Promote Cancer Via Multiple Regulatory Mechanisms.

RNA‐binding Protein Musashi2 Stabilizing Androgen Receptor Drives Prostate Cancer Progression

Comprehensive Analysis of Alternative Splicing Profiling Reveals Novel Events Associated with Prognosis and the Infiltration of Immune Cells in Prostate Cancer.